FDA grants emergency use authorization for a COVID-19 antibody drug

The drug is not authorized to be utilized in individuals hospitalized due to the disease.

Published: May 26, 2021 9:16pm

Updated: May 26, 2021 10:02pm

The U.S. Food and Drug Administration has granted an emergency use authorization for the monoclonal antibody sotrovimab to treat mild-to-moderate COVID-19 infections.

The drug is not authorized to be utilized in individuals hospitalized due to the disease, according to the FDA.

"The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19," the FDA noted. "This treatment has not shown benefit in patients hospitalized due to COVID-19 and monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation."

The Facts Inside Our Reporter's Notebook

Links

Unlock unlimited access

  • No Ads Within Stories
  • No Autoplay Videos
  • VIP access to exclusive Just the News newsmaker events hosted by John Solomon and his team.
  • Support the investigative reporting and honest news presentation you've come to enjoy from Just the News.
  • Just the News Spotlight

    Support Just the News